Advertisement Roche NimbleGen signs strategic alliance with BioDiscovery - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Roche NimbleGen signs strategic alliance with BioDiscovery

Roche NimbleGen, a company of Roche Applied Science, has signed a strategic alliance with BioDiscovery, to offer complete solutions to comparative genomic hybridization microarray customers.

The new high-density 2.1 million probe (HD2) arrays of Roche NimbleGen combined with proprietary software, Nexus Copy Number, of BioDiscovery bring unprecedented power and ease in whole-genome comparative genomic hybridization (CGH) analysis.

As part of this alliance Roche NimbleGen and BioDiscovery will co-market and co-promote their products and services to scientists worldwide. The companies also plan to present data generated from NimbleGen CGH arrays using Nexus software of BioDiscovery to the research community through a series of seminars.

Soheil Shams, president of BioDiscovery, said: “The powerful combination of our technologies enables scientists to analyze data from millions of probes across thousands of samples to quickly arrive at important biological insights. We look forward to expanding our relationship with Roche NimbleGen and furthering the state of technology in genomics research.”